Investment Thesis
Capricor Therapeutics is a pre-revenue clinical-stage pharmaceutical company burning $29.3M annually with zero commercialized products, resulting in accelerating losses (EPS down 96.5% YoY). While the balance sheet is fortress-like with $105.4M in cash and zero debt, the 3.6-year cash runway and complete lack of revenue generation create substantial execution risk with uncertain path to profitability.
Strengths
- Strong balance sheet: $278.7M stockholders equity with zero long-term debt
- Substantial cash reserves of $105.4M providing 3-4 year runway at current burn rate
- Excellent liquidity position: 8.42x current ratio demonstrating operational flexibility
- Conservative capital structure with no debt burden reducing financial stress
Risks
- Complete absence of revenue indicating pre-commercial stage with uncertain product timelines
- Operating losses accelerating: -$36.8M operating income with EPS deteriorating 96.5% YoY
- Significant cash burn of -$34.4M free cash flow annually consuming equity capital
- Pharma development risk: dependent entirely on clinical success, regulatory approval, and market acceptance with no proven products
Key Metrics to Watch
- Revenue achievement and first commercial product launch timeline
- Operating cash burn trend and cash runway extension milestones
- Clinical trial progression and regulatory approval status for pipeline candidates
- Changes in stockholders equity depletion rate and path to profitability
Financial Metrics
Revenue
0.0
Net Income
-33.9M
EPS (Diluted)
$-0.59
Free Cash Flow
-34.4M
Total Assets
326.3M
Cash
105.4M
Profitability Ratios
Gross Margin
N/A
Operating Margin
N/A
Net Margin
N/A
ROE
-12.2%
ROA
-10.4%
FCF Margin
N/A
Balance Sheet & Liquidity
Current Ratio
8.42x
Quick Ratio
8.42x
Debt/Equity
0.00x
Debt/Assets
14.6%
Interest Coverage
N/A
Long-term Debt
N/A
Disclaimer: This analysis is generated by AI based on publicly available SEC EDGAR filings.
It does not include stock price data and should not be considered financial advice.
All fundamental data is sourced from SEC public domain filings.
Always conduct your own research before making investment decisions.
Data Source: SEC EDGAR |
Analysis Date: 2026-05-14T08:05:16.390829 |
Data as of: 2026-03-31 |
Powered by Claude AI